139 related articles for article (PubMed ID: 11240256)
1. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
Kavanagh BD; Khandelwal SR; Schmidt-Ullrich RK; Roberts JD; Shaw EG; Pearlman AD; Venitz J; Dusenbery KE; Abraham DJ; Gerber MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1133-9. PubMed ID: 11240256
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
Kleinberg L; Grossman SA; Piantadosi S; Pearlman J; Engelhard H; Lesser G; Ruffer J; Gerber M
J Clin Oncol; 1999 Aug; 17(8):2593-603. PubMed ID: 10561327
[TBL] [Abstract][Full Text] [Related]
4. Allosteric modification of oxygen delivery by hemoglobin.
Wahr JA; Gerber M; Venitz J; Baliga N
Anesth Analg; 2001 Mar; 92(3):615-20. PubMed ID: 11226087
[TBL] [Abstract][Full Text] [Related]
5. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487
[TBL] [Abstract][Full Text] [Related]
6. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
[TBL] [Abstract][Full Text] [Related]
7. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.
Khandelwal SR; Kavanagh BD; Lin PS; Truong QT; Lu J; Abraham DJ; Schmidt-Ullrich RK
Br J Cancer; 1999 Feb; 79(5-6):814-20. PubMed ID: 10070874
[TBL] [Abstract][Full Text] [Related]
8. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.
Stea B; Shaw E; Pintér T; Hackman J; Craig M; May J; Steffen RP; Suh JH
Br J Cancer; 2006 Jun; 94(12):1777-84. PubMed ID: 16773073
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.
Amorino GP; Lee H; Holburn GE; Paschal CB; Hercules SK; Shyr Y; Steffen RP; Choy H
Radiat Res; 2001 Sep; 156(3):294-300. PubMed ID: 11500138
[TBL] [Abstract][Full Text] [Related]
10. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs.
Pagel PS; Hettrick DA; Montgomery MW; Kersten JR; Steffen RP; Warltier DC
J Pharmacol Exp Ther; 1998 Apr; 285(1):1-8. PubMed ID: 9535987
[TBL] [Abstract][Full Text] [Related]
11. Efaproxiral: a novel radiation sensitiser.
Suh JH
Expert Opin Investig Drugs; 2004 May; 13(5):543-50. PubMed ID: 15155129
[TBL] [Abstract][Full Text] [Related]
12. The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats.
Grinberg OY; Miyake M; Hou H; Steffen RP; Swartz HM
Adv Exp Med Biol; 2003; 530():287-96. PubMed ID: 14562725
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
Choy H; Nabid A; Stea B; Scott C; Roa W; Kleinberg L; Ayoub J; Smith C; Souhami L; Hamburg S; Spanos W; Kreisman H; Boyd AP; Cagnoni PJ; Curran WJ
J Clin Oncol; 2005 Sep; 23(25):5918-28. PubMed ID: 16135463
[TBL] [Abstract][Full Text] [Related]
14. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
15. Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.
Steffen RP; Liard JF; Gerber MJ; Hoffman SJ
Adv Exp Med Biol; 2003; 530():249-59. PubMed ID: 14562722
[TBL] [Abstract][Full Text] [Related]
16. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
Rockwell S; Kelley M
Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166
[TBL] [Abstract][Full Text] [Related]
17. Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat.
Sarraf-Yazdi S; Sheng H; Grocott HP; Bart RD; Pearlstein RD; Steffen RP; Warner DS
Brain Res; 1999 May; 826(2):172-80. PubMed ID: 10224294
[TBL] [Abstract][Full Text] [Related]
18. RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass.
Kilgore KS; Shwartz CF; Gallagher MA; Steffen RP; Mosca RS; Bolling SF
Circulation; 1999 Nov; 100(19 Suppl):II351-6. PubMed ID: 10567328
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
Shulman LN; Buswell L; Riese N; Doherty N; Loeffler JS; von Roemeling RW; Coleman CN
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):349-53. PubMed ID: 10760430
[TBL] [Abstract][Full Text] [Related]
20. The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats.
Miyake M; Grinberg OY; Hou H; Steffen RP; Elkadi H; Swartz HM
Adv Exp Med Biol; 2003; 530():319-29. PubMed ID: 14562728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
